Noninvasive Measures of Liver Fibrosis and Severity of Liver Disease.

Determining the degree of fibrosis is an important step in the assessment of disease severity in patients with chronic liver disease. Liver biopsy has been the gold standard for estimating the extent of inflammation and fibrosis, although the procedure has limitations such as sampling error and vari...

Full description

Bibliographic Details
Published in:Gastroenterology & Hepatology Vol. 12; no. 1; pp. 33 - 41
Main Authors: Lucero, Catherine, Brown Jr., Robert S.
Format: pictorial protocol review tables/charts Journal Article
Published: Gastro-Hep Communications, Inc Jan2016
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112855259&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 112855259
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15547914
        6N5B
      jtl: Gastroenterology & Hepatology
      issn: 15547914
      maglogo: N
    pubinfo:
      dt: Jan2016
      vid: 12
      iid: 1
      pid: 72163
      pub: Gastro-Hep Communications, Inc
      place: New York, New York
    artinfo:
      ui:
        112855259
        112855259
        112855259
        112855259
      ppf: 33
      ppct: 8
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Noninvasive Measures of Liver Fibrosis and Severity of Liver Disease.
      aug:
        au:
          Lucero, Catherine
          Brown Jr., Robert S.
        affil: assistant professor of medicine, Center for Liver Disease and Transplantation, Weill Cornell Medical Center, New York, New York
      sug:
        subj:
          Acoustics
          Hypertension, Portal
          Liver Diseases
          Sampling Error
          Functional Assessment
          Fibrosis
      ab: Determining the degree of fibrosis is an important step in the assessment of disease severity in patients with chronic liver disease. Liver biopsy has been the gold standard for estimating the extent of inflammation and fibrosis, although the procedure has limitations such as sampling error and variability. Noninvasive testing has been shown to be equally predictive in ruling out fibrosis or ruling in advanced fibrosis. Serum biomarkers and imaging-based tests have more limited predictive ability when classifying intermediate stages, but these tools can help identify which patients should receive antiviral treatment sooner and require ongoing cancer surveillance without the need for biopsy. Using a combination of serum markers and imaging tests may also be helpful in providing functional assessment of portal hypertension in patients with chronic liver disease.
      pubtype: Academic Journal
      doctype:
        pictorial
        protocol
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N